Favaloro Emmanuel J, Mohammed Soma, Vong Ronny, McVicker Wendy, Chapman Kent, Swanepoel Priscilla, Kershaw Geoff, Cai Nancy, Just Sarah, Connelly Lynne, Prasad Ritam, Brighton Timothy, Pasalic Leonardo
Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, Australia.
Sydney Centres for Thrombosis and Haemostasis, Westmead, Australia.
Am J Clin Pathol. 2021 Sep 8;156(4):661-678. doi: 10.1093/ajcp/aqab004.
To verify a single platform of hemostasis instrumentation, the ACL TOP 50 Family, comprising 350, 550, and 750 instruments, across a large network of 60 laboratories.
Comparative evaluations of instrument classes (350 vs 550 and 750) were performed using a large battery of test samples for routine coagulation tests, comprising prothrombin time/international normalized ratio, activated partial thromboplastin time (APTT), thrombin time, fibrinogen and D-dimer, and using HemosIL reagents. Comparisons were also made against existing equipment (Diagnostica Stago Satellite, Compact, and STA-R Evolution) and existing reagents to satisfy national accreditation standards. Verification of manufacturer normal reference ranges (NRRs) and generation of an APTT heparin therapeutic range were undertaken.
The three instrument types were verified as a single instrument class, which will permit standardization of methods and NRRs across all instruments (n = 75) to be deployed in 60 laboratories. In particular, ACL TOP 350 test result data were similar to ACL TOP 550 and 750 and showed no to limited bias. All manufacturer NRRs were verified with occasional minor variance.
This ACL TOP 50 Family (350, 550, and 750) verification will enable harmonization of routine coagulation across all laboratories in the largest public pathology network in Australia.
在由60个实验室组成的大型网络中,验证止血检测仪器的单一平台ACL TOP 50系列,该系列包括350、550和750型号的仪器。
使用大量用于常规凝血检测的测试样本,包括凝血酶原时间/国际标准化比值、活化部分凝血活酶时间(APTT)、凝血酶时间、纤维蛋白原和D-二聚体,并使用HemosIL试剂,对仪器型号(350与550和750)进行比较评估。还与现有设备(Diagnostica Stago Satellite、Compact和STA-R Evolution)及现有试剂进行比较,以满足国家认证标准。对制造商的正常参考范围(NRR)进行验证,并生成APTT肝素治疗范围。
这三种仪器型号被验证为单一仪器类别,这将允许在60个实验室中部署的所有仪器(n = 75)的方法和NRR实现标准化。特别是,ACL TOP 350的测试结果数据与ACL TOP 550和750相似,且显示无偏差或偏差有限。所有制造商的NRR均得到验证,偶尔有微小差异。
此次ACL TOP 50系列(350、550和750)验证将使澳大利亚最大的公共病理网络中所有实验室的常规凝血检测实现统一。